Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B. Hanauer,B. Feagan,8 Authors,P. Rutgeerts
2002 · DOI: 10.1016/S0140-6736(02)08512-4
The Lancet · 136 Citations
TLDR
Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if infliximab treatment is maintained every 8 weeks.